Glenmark Pharmaceuticals Limited
GLENMARK
Rang in Aktien
#2717
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Aktienkurs
$24.69
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$6.97B
Veränderung (1 Tag)
-0.60%
Veränderung (1 Jahr)
16.71%
Land
IN
Handel Glenmark Pharmaceuticals Limited (GLENMARK)
Kategorie
Healthcare
Operative Marge für Glenmark Pharmaceuticals Limited (GLENMARK)
Operative Marge zum October 2026 TTM: 20.24%
Laut den neuesten Finanzberichten und dem Aktienkurs von Glenmark Pharmaceuticals Limited beträgt die aktuelle operative Marge (TTM) 20.24%. Am Ende des Jahres 2024 lag die operative Marge bei 26.84%.
Historie der operativen Marge von Glenmark Pharmaceuticals Limited von 2004 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 20.24% | -35.36% |
| 2025 | 31.31% | 16.65% |
| 2024 | 26.84% | 182.23% |
| 2023 | 9.51% | -37.84% |
| 2022 | 15.30% | -0.71% |
| 2021 | 15.41% | 28.10% |
| 2020 | 12.03% | -26.56% |
| 2019 | 16.38% | 9.05% |
| 2018 | 15.02% | -10.01% |
| 2017 | 16.69% | 6.51% |
| 2016 | 15.67% | 30.47% |
| 2015 | 12.01% | -19.07% |
| 2014 | 14.84% | -17.09% |
| 2013 | 17.90% | 15.04% |
| 2012 | 15.56% | -28.10% |
| 2011 | 21.64% | -1.23% |
| 2010 | 21.91% | -11.90% |
| 2009 | 24.87% | -29.77% |
| 2008 | 35.41% | 22.65% |
| 2007 | 28.87% | 95.20% |
| 2006 | 14.79% | -28.89% |
| 2005 | 20.80% | 53.96% |
| 2004 | 13.51% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.87% |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.